BIOCON Financial Statement Analysis
|
||
|
The Revenues of BIOCON have increased by 3.43% YoY .
The Earnings Per Share (EPS) of BIOCON has decreased by -0.94 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BIOCON Last 5 Annual Financial Results
[BOM: 532523|NSE : BIOCON]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹15,262 Cr | ₹14,756 Cr | ₹11,174 Cr | ₹8,184 Cr | ₹7,143 Cr |
| Expenses | ₹12,243 Cr | ₹11,559 Cr | ₹9,055 Cr | ₹6,691 Cr | ₹5,841 Cr |
| Operating Profit (Excl OI) | ₹3,019 Cr | ₹3,197 Cr | ₹2,120 Cr | ₹1,493 Cr | ₹1,302 Cr |
| Other Income | ₹1,356 Cr | ₹968 Cr | ₹768 Cr | ₹690 Cr | ₹605 Cr |
| Interest | ₹897 Cr | ₹974 Cr | ₹419 Cr | ₹68 Cr | ₹58 Cr |
| Depreciation | ₹1,687 Cr | ₹1,569 Cr | ₹1,113 Cr | ₹814 Cr | ₹715 Cr |
| Profit Before Tax | ₹1,887 Cr | ₹1,525 Cr | ₹897 Cr | ₹983 Cr | ₹1,068 Cr |
| Profit After Tax | ₹1,429 Cr | ₹1,298 Cr | ₹643 Cr | ₹772 Cr | ₹846 Cr |
| Consolidated Net Profit | ₹1,013 Cr | ₹1,023 Cr | ₹463 Cr | ₹648 Cr | ₹741 Cr |
| Earnings Per Share (Rs) | ₹8.44 | ₹8.52 | ₹3.85 | ₹5.40 | ₹6.17 |
| PAT Margin (%) | 9.32 | 8.69 | 5.70 | 9.40 | 11.85 |
| ROE(%) | 7.03 | 7.00 | 4.98 | 9.83 | 12.03 |
| ROCE(%) | 7.43 | 7.03 | 5.37 | 8.30 | 10.56 |
| Total Debt/Equity(x) | 0.84 | 0.81 | 1.01 | 0.60 | 0.58 |
Key Financials |
||
| Market Cap | : | ₹ 53,219.3 Cr |
| Revenue (TTM) | : | ₹ 16,475.8 Cr |
| Net Profit(TTM) | : | ₹ 762.5 Cr |
| EPS (TTM) | : | ₹ 5.7 |
| P/E (TTM) | : | 69.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BIOCON | 1.5% | 1.3% | 19.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.5% | -1.9% | -3% |
| DIVIS LABORATORIES | 1.8% | 1.3% | 10.8% |
| CIPLA | -0.2% | -0.7% | 1.9% |
| TORRENT PHARMACEUTICALS | 2% | 2.4% | 11.2% |
| DR REDDYS LABORATORIES | -1% | 2.5% | -4.4% |
| MANKIND PHARMA | 2.4% | -2.2% | -20.4% |
| ZYDUS LIFESCIENCES | 0.4% | -1.1% | -4.7% |
| LUPIN | -0.4% | 3.2% | -1.6% |
BIOCON Revenues
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 3.43 % |
| 5 Yr CAGR | 20.90 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹15,262 Cr | 3.43 | |
| Mar2024 | ₹14,756 Cr | 32.05 | |
| Mar2023 | ₹11,174 Cr | 36.54 | |
| Mar2022 | ₹8,184 Cr | 14.57 | |
| Mar2021 | ₹7,143 Cr | - | |
BIOCON Operating Profit
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -5.57 % |
| 5 Yr CAGR | 23.39 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹3,019 Cr | -5.57 | |
| Mar2024 | ₹3,197 Cr | 50.82 | |
| Mar2023 | ₹2,120 Cr | 42.00 | |
| Mar2022 | ₹1,493 Cr | 14.63 | |
| Mar2021 | ₹1,302 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -8.68 % |
| 5 Yr CAGR | 2.06 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 19.78% | -8.68 | |
| Mar2024 | 21.66% | 14.18 | |
| Mar2023 | 18.97% | 4.00 | |
| Mar2022 | 18.24% | 0.05 | |
| Mar2021 | 18.23% | - | |
BIOCON Profit After Tax
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -0.90 % |
| 5 Yr CAGR | 8.16 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,013 Cr | -0.90 | |
| Mar2024 | ₹1,023 Cr | 120.99 | |
| Mar2023 | ₹463 Cr | -28.64 | |
| Mar2022 | ₹648 Cr | -12.44 | |
| Mar2021 | ₹741 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 7.25 % |
| 5 Yr CAGR | -5.83 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 9.32 % | 7.25 | |
| Mar2024 | 8.69 % | 52.46 | |
| Mar2023 | 5.7 % | -39.36 | |
| Mar2022 | 9.4 % | -20.68 | |
| Mar2021 | 11.85 % | - | |
BIOCON Earnings Per Share (EPS)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -0.94 % |
| 5 Yr CAGR | 8.15 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹8.44 | -0.94 | |
| Mar2024 | ₹8.52 | 121.30 | |
| Mar2023 | ₹3.85 | -28.70 | |
| Mar2022 | ₹5.40 | -12.48 | |
| Mar2021 | ₹6.17 | - | |
BIOCON Return on Capital Employed (ROCE)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 5.69 % |
| 5 Yr CAGR | -8.41 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 7.43% | 5.69 | |
| Mar2024 | 7.03% | 30.91 | |
| Mar2023 | 5.37% | -35.30 | |
| Mar2022 | 8.3% | -21.40 | |
| Mar2021 | 10.56% | - | |
BIOCON Share Price vs Sensex
| Current Share Price | : | ₹398.1 |
| Current MarketCap | : | ₹ 53,219.3 Cr |
| Updated EOD on | : | Dec 24,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | 1.5% |
1.3% |
19.5% |
| SENSEX | 1% |
0.6% |
7.8% |
BIOCON related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE 400 MIDSMALLCAP INDEX | 1.9% | 0.3% | -2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP150 MOMENTUM 50 | 2.2% | -0.2% | -6.6% |
| NIFTY MIDSMALLCAP 400 | 2.1% | 0.6% | -0.9% |
| NIFTY 500 EQUAL WEIGHT | 2.1% | 0.3% | -1.8% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 1.9% | 0.6% | 0.9% |
| NIFTY MIDCAP 150 | 1.8% | 0.8% | 3.1% |
You may also like the below Video Courses
FAQ about BIOCON Financials
How the annual revenues of BIOCON have changed ?
The Revenues of BIOCON have increased by 3.43% YoY .
How the Earnings per Share (EPS) of BIOCON have changed?
The Earnings Per Share (EPS) of BIOCON has decreased by -0.94 % YoY .
Check out Intrinsic Value of Peers of BIOCON
Compare Stock Analytics of Peers of BIOCON
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
